QualityStocks would like to highlight Advanced Cell Technology, Inc., (OTCBB: ACTC), a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. The company applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab bench to the bedside.
In the company’s news yesterday,
Advanced Cell Technology announced it has treated the final patient in the first patient group participating in its phase 1/2 clinical trial for Stargardt’s macular dystrophy (SMD), which causes progressive vision loss and eventual blindness. The trial uses retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) as treatment for SMD.
The outpatient transplant surgery was performed July 27 at Moorfields Eye Hospital in London without any complications. This is the tenth patient overall to now be treated with Advanced Cell’s RPE cell therapy. The phase 1/2 trial, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD, will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format.
Gary Rabin, Advanced Cell chairman and CEO, said the company anticipates receiving clearance to initiate the treatment of the second patient cohort in the coming weeks.
“This is a significant month for the company,” Rabin stated in the press release. “One year ago we treated the first of our patients in our two U.S. clinical trials. The one-year follow-up for those initial patients indicates that the improvements in visual acuity we initially reported have in fact persisted now for a year. Indeed, we are consistently observing improvements in subjective and objective visual acuity for patients being treated at the various clinical centers involved in our trials. Again, these trials are still at very early stages, but these preliminary results indicate that we are on the right track.”
The European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has officially designated Advanced Cell’s hESC-derived RPE cells as an orphan medicinal product for the treatment of SMD.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
